CuraTeQ bevacizumab
Bevacizumab biosimilar developed by CuraTeQ Biologics (Aurobindo). Reference product Avastin.
Brands by market: Brand not published by CDSCO (India) ยท Commercial partner or holder: CuraTeQ Biologics
FDAnot listed
EMAnot listed
CDSCOMay 2026permitted
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
CDSCO
India
Central Drugs Standard Control OrganisationApprovedBrand
Not published by CDSCO (INN only)
Holder or applicant
CuraTeQ Biologics Private Limited
Pathway
Similar Biologic, manufacture and marketing permission
Approved
May 2026
Application or permission
MF/BIO/26/000060
Indications as licensed
Metastatic colorectal cancer and other reference indications
Presentations
100 mg/4 mL and 400 mg/16 mL
Source
S011
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- CDSCOMay 2026CDSCO permission granted
Sources
Planning bevacizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.